 |
Synthetic double-stranded siRNA oligonucleotide against caspase 2 mRNA |
|---|---|
| Trade Name | |
| Orphan Indication | Anterior ischemic optic neuropathy |
| USA Market Approval | USA |
| USA Designation Date | 2012-09-25 00:00:00 |
| Sponsor | Quark Pharmaceuticals, Inc.;6501 Dumbarton Circle;Fremont, California, 94555 |
